Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. Its products include OMNI surgical system, an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeons to perform procedures for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure; and SION surgical instrument, a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The company also offers TearCare system, a dry eye device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.

Sight Sciences Inc.

Lake Street analyst Frank Takkinen reiterated a Buy rating on Sight Sciences today and set a price target of $12.00. Takkinen covers the Healthcare...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SGHT	$8.10	-2.17%	138.79K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SGHT	$8.10	-2.2%	138.79K
3
4
5
6

SGHT

SGHT

Get Sight Sciences Inc. Data in Excel

Get Sight Sciences Inc. Data in Excel